Besides, in our center, patients with high eIF4E significantly had shorter 3-year OS compared to that with low eIF4E in all AML patient cohorts (Figure 6C, p < 0.05) and the de novo cohort (Figure 6D, p < 0.05). Here, EIF4E is linked to acute myeloid leukemia.